The MHRA is consulting with UK stakeholders to gather feedback and comments on a revised international guideline, M4Q(R2).
Similar Posts
Transparency data: MHRA Performance Data
Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.
Patients to benefit as UK and US regulators forge new collaboration on medical technologies and AI
Enhanced collaboration with the US on med tech regulation, with accelerated innovation, strengthened patient safety, and reduced transatlantic barriers to market access.
Field Safety Notices: 22-26 December 2025
List of Field Safety Notices for 22-26 December 2025
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.
Parents and caregivers advised to stop all use of specific brand of kids’ magnesium gummies due to the presence of an undeclared prescription-only medicine
Parents and caregivers who have purchased Nutrition Ignition Kids Magnesium Glycinate Gummies should stop giving them to children and safely dispose of any remaining product. It is recommended that advice be sought from a healthcare professional if a child has any side effects that are of concern.
Research: Report of The Commission on Human Medicines Isotretinoin Implementation Advisory Expert Working Group
Report of Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.